结核病防控进展

陈诚; 刘炯雅; 孙郑; 陈驰; 吴文娟; 刘巧; 竺丽梅; 陆伟

doi:10.16462/j.cnki.zhjbkz.2025.04.001

结核病防控进展

doi: 10.16462/j.cnki.zhjbkz.2025.04.001

陈诚¹,
刘炯雅³,
孙郑³,
陈驰³,
吴文娟³,
刘巧¹,
竺丽梅¹,
陆伟^2, ,

1.
江苏省疾病预防控制中心慢性传染病防制所，南京 210009
2.
江苏省疾病预防控制局监测预警处，南京 210009
3.
南京医科大学公共卫生学院流行病与卫生统计学系，南京 211166

基金项目:

江苏省“十四五”流行病学重点学科 ZDXK202250

详细信息

通讯作者:
陆伟, E-mail: weiluxx@163.com

中图分类号: R181.3;R183.3
计量
- 文章访问数: 167
- HTML全文浏览量: 48
- PDF下载量: 39
- 被引次数: 0
出版历程
- 收稿日期: 2024-11-07
- 修回日期: 2025-01-19
- 刊出日期: 2025-04-10

Progress in tuberculosis prevention and control

1.
Department of Chronic Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
2.
Monitoring and Early Warning Department, Jiangsu Provincial Disease Control and Prevention Bureau, Nanjing 210009, China
3.
Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China

Funds:

Jiangsu Province "14th Five-Year Plan" Key Discipline of Epidemiology ZDXK202250

More Information

Corresponding author: LU Wei, E-mail: weiluxx@163.com

摘要

摘要: 结核病(tuberculosis, TB)作为全球重大的公共卫生问题，一直对人类的生命健康构成严重威胁，2023年全球估算新发TB患者约1 080万，发病率为134/10万。为实现WHO 2035年终结TB这一目标，近年来世界各国采取了多项措施，包括加强TB监测和报告、提高诊断水平、开展积极有效的治疗、加强疫苗接种以及开展公众健康教育等，以控制TB的流行。这些措施使TB的流行得到了有效遏制。通过参阅文献、指南、专家共识和技术规范，对当前TB的流行现状、诊治技术、防治策略等方面进行综述，为TB的防控提供参考依据。
- 结核病 /
- 流行 /
- 诊断治疗 /
- 防治措施 /
- 疫苗
Abstract: Tuberculosis (TB), as a major global public health issue, continues to pose a severe threat to human life and health. In 2023, it was estimated that approximately 10.8 million new TB cases occurred globally, with an incidence rate of 134 per 100 000 population. To achieve the END TB strategy by 2035, countries worldwide have implemented various measures in recent years, including enhancing TB surveillance and reporting, improving diagnostic capabilities, promoting effective treatment, strengthening vaccination efforts, and conducting public health education. These efforts have effectively curbed the spread of TB. This article reviews the current epidemiological situation of TB, diagnostic and treatment technologies, and prevention strategies by referencing literature, guidelines, expert consensus, and technical standards, aiming to provide a reference for TB prevention and control.
- Tuberculosis /
- Epidemiology /
- Diagnosis and treatment /
- Prevention measures /
- Vaccine

HTML全文

参考文献(25)

[1]	World Health Organization. Global tuberculosis report 2023[EB/OL]. (2023-11-01)[2023-11-03]. https://iris.who.int.bitstream/han-dle/10665/373828/9789240083851-eng.pdf?sequence=1.
[2]	World Health Organization. Global tuberculosis report 2024[M/OL]. (2024-10-29)[2024-11-03]. https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1.
[3]	Zheng HW, Xiao J, Yang HM, et al. Epidemiology of tuberculosis among children in Beijing, China, 2012-2021[J]. Epidemiol Infect, 2024, 152: e44. DOI: 10.1017/S0950268824000414.
[4]	Zhang HY, He YY, Davies Forsman L, et al. Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis[J]. Front Pharmacol, 2023, 13: 1032674. DOI: 10.3389/fphar.2022.1032674.
[5]	马慧敏, 张丽帆, 刘晓清. 潜伏性结核感染进展为活动性结核病的机制研究[J]. 结核病与肺部健康杂志, 2020, 1(4): 276-280. DOI: 10.3969/j.issn.2096-8493.2020.03.014. Ma HM, Zhang LF, Liu XQ. Research progress on the mechanism of latent tuberculosis infection progressing to active tuberculosis[J]. J Tuberc Lung Dis, 2020, 1(4): 276-280. DOI: 10.3969/j.issn.2096-8493.2020.03.014.
[6]	Behr MA, Kaufmann E, Duffin J, et al. Latent tuberculosis: two centuries of confusion[J]. Am J Respir Crit Care Med, 2021, 204(2): 142-148. DOI: 10.1164/rccm.202011-4239PP.
[7]	Reichler MR, Khan A, Sterling TR, et al. Risk and timing of tuberculosis among close contacts of persons with infectious tuberculosis[J]. J Infect Dis, 2018, 218(6): 1000-1008. DOI: 10.1093/infdis/jiy265.
[8]	Chakaya J, Petersen E, Nantanda R, et al. The WHO global tuberculosis 2021 report-not so good news and turning the tide back to end TB[J]. Int J Infect Dis, 2022, 124: S26-S29. DOI: 10.1016/j.ijid.2022.03.011.
[9]	中国医疗保健国际交流促进会临床微生物与感染分会, 中华医学会检验医学分会临床微生物学组, 中华医学会微生物学和免疫学分会临床微生物学组. 综合医院结核分枝杆菌感染实验室检查共识[J]. 中华检验医学杂志, 2022, 45(4): 343-353. DOI: 10.3760/cma.j.cn114452-20211118-00722. China International Exchange and Promotive Association for Medical and Health Care Clinical Microbiology and Infection Branch, Clinical Microbiology Group of the Chinese Society of Laboratory Medicine, Clinical Microbiology Group of the Chinese Society of Microbiology and Immunology. Chinese expert consensus on the best practice of microbiological examination for Mycobacterium tuberculosis infection/tuberculosis in general hospital[J]. Chin J Lab Med, 2022, 45(4): 343-353. DOI: 10.3760/cma.j.cn114452-20211118-00722.
[10]	杜威, 刘春雨, 王路生, 等. 结核病发病机制的研究进展[J]. 中国人兽共患病学报, 2022, 38(3): 217-225. DOI: 10.3969/j.issn.1002-2694.2022.00.005. Du W, Liu CY, Wang LS, et al. Research progress in the pathogenesis of tuberculosis[J]. Chinese Journal of Zoonoses, 2022, 38(3): 217-225. DOI: 10.3969/j.issn.1002-2694.2022.00.005.
[11]	Luies L, du Preez I. The echo of pulmonary tuberculosis: mechanisms of clinical symptoms and other disease-induced systemic complications[J]. Clin Microbiol Rev, 2020, 33(4): e00036-20. DOI: 10.1128/CMR.00036-20.
[12]	Pepperell CS. Evolution of tuberculosis pathogenesis[J]. Annu Rev Microbiol, 2022, 76: 661-680. DOI: 10.1146/annurev-micro-121321-093031.
[13]	杨国元, 黄福岚, 杨彩虹. 结核分枝杆菌利福平耐药的分子机制及检测技术[J]. 畜牧兽医科技信息, 2024, (3): 24-26. DOI: 10.13300/j.cnki.yfsyxjz.2024.03.008. Yang GY, Huang FL, Yang CH. Molecular mechanisms and detection techniques of rifampicin resistance in mycobacterium tuberculosis[J]. Livestock and Poultry Science and Veterinary Medicine Information, 2024, (3): 24-26. DOI: 10.13300/j.cnki.yfsyxjz.2024.03.008.
[14]	World Health Organization, Global tuberculosis report 2023[M/OL]. (2023-11-03)[2023-11-17]. https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf?sequenc-e=1.
[15]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. tests for tuberculosis infection[M/OL]. (2022-09-20)[2023-09-20]. https://iris.who.int/bitstream/handle/10665/362936/9789240056084-eng.pdf?sequence=1.
[16]	Li JL, Lu JB, Wang GZ, et al. Past, present and future of Bacillus calmette-guérin vaccine use in China[J]. Vaccines, 2022, 10(7): 1157. DOI: 10.3390/vaccines10071157.
[17]	Kim SH, Jo KW, Shim TS. QuantiFERON-TB Gold PLUS versus QuantiFERON-TB Gold In-Tube test for diagnosing tuberculosis infection[J]. Korean J Intern Med, 2020, 35(2): 383-391. DOI: 10.3904/kjim.2019.002.
[18]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management[M/OL]. (2018-02-19)[2018-02-19]. https://iris.who.int/bitstream/handle/10665/260233/9789241550239-eng.pdf?sequence=1.
[19]	Chen H, Zhang H, Cheng J, et al. Adherence to preventive treatment for latent tuberculosis infection in close contacts of pulmonary tuberculosis patients: a cluster-randomized controlled trial in China[J]. Int J Infect Dis, 2024, 147: 107196. DOI: 10.1016/j.ijid.2024.107196.
[20]	World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment[J]. 2019.
[21]	Junqueira-Kipnis AP, Leite LCC, Croda J, et al. Advances in the development of new vaccines for tuberculosis and Brazil's role in the effort forward the end TB strategy[J]. Mem Inst Oswaldo Cruz, 2024, 119: e240093. DOI: 10.1590/0074-02760240093.
[22]	Valencia-Hernandez AM, Zhao GZ, Miranda-Hernandez S, et al. A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts[J]. Vaccine, 2024, 42(24): 126291. DOI: 10.1016/j.vaccine.2024.126291.
[23]	Karunakaran KP, Yu H, Jiang XZ, et al. Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface lipoprotein Mpt83 as a T cell antigen useful for vaccine development[J]. Vaccine, 2024, 42(24): 126266. DOI: 10.1016/j.vaccine.2024.126266.
[24]	WHO. The end TB strategy[M/OL]. (2015-08-16)[2024-11-03]. https://iris.who.int/bitstream/handle/10665/331326/WHO-HTM-TB-2015.19-eng.pdf?sequence=1.
[25]	禄晓龙, 王芸. 1991-2015年我国结核病防治政策的特点分析[J]. 现代医药卫生, 2015, 31(22): 3397-3398, 3401. DOI: 10.3969/j.issn.1009-5519.2015.22.012. Lu XL, Wang Y. Analysis of characteristics of TB prevention and treatment policies in our country during 1991-2015[J]. J Mod Med Health, 2015, 31(22): 3397-3398, 3401. DOI: 10.3969/j.issn.1009-5519.2015.22.012.